US Respiratory Drug Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2025

US respiratory drug market was around $15.0 billion in 2018 and is anticipated to grow at a substantial rate of 7.6% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in the US. Asthma is a chronic inflammation of the lung airways that causes breathlessness and coughing. The number of people with asthma grows every year in the US. According to the CDC, there are around 26 million asthma patients in the US, among which, nearly 18.9 million are adults and 7.1 million are children. Moreover, the prevalence of asthma in children is nearly 9.4% which is higher than that of adults accounting to around 7.7%, and higher in females nearly 9.2% than in males accounting to 7% of total asthma patients. This is one of the primary reasons for the high growth rate of the market within the country.

To Request a Sample of our Report on US Respiratory Drug Market: https://www.omrglobal.com/request-sample/us-respiratory-drug-market

The US respiratory drug market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the US. According to the Centers for Disease Control and Prevention (CDC) 2017, there are around 26 million asthmatics in the US, among which, nearly 18.9 million are adults and 7.1 million are children. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

(Get 15% Discount on Buying this Report)

A full Report of US Respiratory Drug Market is Available @ https://www.omrglobal.com/industry-reports/us-respiratory-drug-market

US Respiratory Drug Market Segmentation

By Route of Administration

· Oral

· Injectable

· Inhalable

· France Respiratory Drug Market by Application

· Asthma

· Chronic Obstructive Pulmonary Disease (COPD)

By End-User

· Homecare

· Hospitals and Clinics

Regional Analysis

· US

· Canada

Company Profiles

· Air Liquide S.A.

· Aradigm Corp.

· AstraZeneca PLC

· Baxter International Inc.

· Boehringer Ingelheim International GmbH

· F. Hoffmann-La Roche Ltd.

· GlaxoSmithKline PLC

· Merck & Co.

· Novartis AG

· Omron Healthcare Inc.

· Pfizer Inc.

· Pulmatrix Inc.

· ResMed Corp.

· Savara, Inc.

· Sunovion Pharmaceuticals

· Takeda Pharmaceutical Company Ltd.

· Teva Pharmaceuticals Industries Ltd.

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.